英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03696 英矽智能

已收盘 02-06 16:08:02

62.150

-5.850

-8.60%

最高67.950	最低61.500	成交量213.31万
今开65.450	昨收68.000	日振幅9.49%
总市值355.26亿	流通市值355.26亿	总股本5.72亿
成交额1.37亿	换手率0.37%	流通股本5.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03696","market":"HK","secType":"STK","nameCN":"英矽智能","latestPrice":62.15,"timestamp":1770365282581,"preClose":68,"halted":0,"volume":2133100,"delay":0,"changeRate":-0.08602941176470591,"floatShares":571622000,"shares":571622000,"eps":-0.238,"marketStatus":"已收盘","change":-5.85,"latestTime":"02-06 16:08:02","open":65.45,"high":67.95,"low":61.5,"amount":136928191,"amplitude":0.094853,"askPrice":62.2,"askSize":29500,"bidPrice":62.15,"bidSize":7500,"shortable":0,"etf":0,"ttmEps":-0.624,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"listingDate":1767024000000,"exchange":"SEHK","adjPreClose":68,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":1.02531,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03696","defaultTab":"news","newsList":[{"id":"1199741493","title":"英矽智能任命张海乐博士为临床开发副总裁，主攻肿瘤领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1199741493","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199741493?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:01","pubTimestamp":1770382909,"startTime":"0","endTime":"0","summary":"人工智能驱动的生物技术公司英矽智能宣布一项重要人事任命，张海乐博士正式加入公司，担任临床开发副总裁一职，将全面负责肿瘤学领域的临床开发战略与执行。\n张海乐博士在医学领域拥有深厚的学术背景和丰富的行业经验。此次任命将进一步加强英矽智能在肿瘤药物研发方面的领导力，加速其创新疗法从实验室向临床应用的转化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03696"],"gpt_icon":0},{"id":"2609020536","title":"【券商聚焦】中泰国际：政策继续支持高品质创新药与高端医疗器械","url":"https://stock-news.laohu8.com/highlight/detail?id=2609020536","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609020536?lang=zh_cn&edition=full","pubTime":"2026-02-06 08:40","pubTimestamp":1770338454,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际发布医药行业2月投资策略，生医疗保健指数1月上涨8.6%，跑赢恒生指数1.7个百分点，主因：1)CXO板块多家企业发布盈喜预告，推动股价上涨。3)国家医保局发布政策支持高品质手术机器人获溢价，医疗器械板块中相关个股上涨。该机构指，国家药监局继续支持高品质创新药发展。中国生物制药本身在肝病、自免、呼吸、肿瘤等领域已有丰富布局，本次通过收购将夯实心血管领域的竞争力。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974664","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","02269","LU0456827905.SGD","LU0327786744.USD","LU0359201612.USD","LU0417516738.SGD","LU0456846285.SGD","LU0320764599.SGD","01177","BK1191","06978","HK0000165453.HKD","LU2125910500.SGD","LU0043850808.USD","SG9999002463.SGD","09996","IE00B0JY6N72.USD","LU2045819591.USD","SG9999002562.SGD","LU0181495838.USD","BK1574","LU0140636845.USD","LU0516422440.USD","BK1576","LU0516423091.SGD","LU0348735423.USD","LU2039709279.SGD","LU0348825331.USD","LU0516422366.SGD","159883","LU0516423174.USD","LU0708995583.HKD","LU0516422952.EUR","LU0823426308.USD","BK1222","LU0572944931.SGD","LU0359202008.SGD","02359","LU0326950275.SGD","03696","LU0039217434.USD","BK1610","LU0052750758.USD","BK1515","IE00BZ08YT58.USD","LU1242518857.USD","LU0823426480.USD","IE00BZ08YS42.EUR","09997","LU0307460666.USD"],"gpt_icon":0},{"id":"1152225881","title":"英矽智能提名外周限制性NLRP3抑制剂ISM5059为临床前候选药物，用于治疗多种炎症及代谢适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225881","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152225881?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:11","pubTimestamp":1770297103,"startTime":"0","endTime":"0","summary":"人工智能驱动的生物技术公司英矽智能宣布，已提名其候选药物ISM5059作为临床前候选化合物。ISM5059是一种具有外周限制性的NLRP3抑制剂，旨在治疗多种炎症和代谢相关疾病。\n该候选药物的提名标志着其在药物研发管线中取得了重要进展。ISM5059通过精准靶向NLRP3炎症小体，有望为相关疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03696"],"gpt_icon":0},{"id":"1174600892","title":"英矽智能（03696）发布2026年1月股份变动月报，已发行股份增加至5.71622亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1174600892","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174600892?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:37","pubTimestamp":1770280670,"startTime":"0","endTime":"0","summary":"英矽智能于2026年2月5日公布2026年1月股份变动月报表。报告期为2026年1月1日至2026年1月31日。已发行股份从上月的557,418,500股增加至571,622,000股，增发14,203,500股。该新增股份于2026年1月21日因悉数行使超额配股权而发行。库存股份数量本月无变化，仍为0股。期权及股权激励方面，首次公开发行前的多项股权激励计划合计期末剩余可行使股份期权31,571,462股，仅有部分期权失效24,058股；首次公开发行后的购股权计划保有27,870,925股期权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"gpt_icon":1},{"id":"1176795349","title":"英矽智能获Menarini集团500万美元里程碑付款，核心药物Men2501实现首次人体给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1176795349","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176795349?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:02","pubTimestamp":1770127372,"startTime":"0","endTime":"0","summary":"人工智能驱动的生物技术公司英矽智能宣布，其合作伙伴Menarini集团已向其支付一笔500万美元的里程碑款项。此次付款的触发条件，是双方合作开发的创新药物Men2501成功达成首次人体（FIH）研究的重大进展。\n这一里程碑标志着Men2501的临床开发迈出了关键一步，为后续研究奠定了坚实基础。该成就不仅验证了项目的科学价值，也体现了双方战略合作的高效执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"32bc88debe3c17bc57e22a6f6b3dcca5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696","BK1141"],"gpt_icon":0},{"id":"2608786488","title":"【国海医药 | 英硅智能】与齐鲁制药达成合作，持续验证AI制药能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2608786488","media":"国海Healthcare","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608786488?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:16","pubTimestamp":1770106566,"startTime":"0","endTime":"0","summary":"事件：2026年1月27日，英硅智能发布公告：公司与齐鲁制药签署战略合作协议，双方将围绕心血管与代谢类疾病领域，利用英硅智能的Pharma.AI平台进行小分子抑制剂的研发。持续达成研发合作，AI制药能力不断被认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020317010697a4a3c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020317010697a4a3c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01477","BK1515","09939","BK1574","BK1141","03696","BK1191"],"gpt_icon":0},{"id":"2608258878","title":"西南证券：首次覆盖英硅智能(03696)建议积极关注 创新能力期待兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2608258878","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608258878?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:57","pubTimestamp":1770105452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，预计英硅智能2025-2027年对应营业收入分别为0.59、1.55和2.02亿美元，对应PS为78倍、30倍和23倍。公司AI平台创新能力得到验证，长期发展值得期待，随着更多管线资产进入临床和对外授权，公司有望迎来持续的价值兑现。首次覆盖，建议积极关注。预计2026年启动IIb或者III期临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03696","BK0028","BK1141","600369","BK0276","BK0183","BK0188","BK0012"],"gpt_icon":0},{"id":"2608540878","title":"英硅智能创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2608540878","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608540878?lang=zh_cn&edition=full","pubTime":"2026-02-03 09:57","pubTimestamp":1770083860,"startTime":"0","endTime":"0","summary":"格隆汇2月3日丨英硅智能(03696.HK)涨12.03%，报67.5000港元，股价创历史新高，总市值385.84亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203095903a4755721&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203095903a4755721&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","BK1141"],"gpt_icon":0},{"id":"2608819940","title":"英硅智能(03696)获美纳里尼3900万港元里程碑付款，合作项目MEN2501完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2608819940","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608819940?lang=zh_cn&edition=full","pubTime":"2026-02-03 08:07","pubTimestamp":1770077255,"startTime":"0","endTime":"0","summary":"英硅智能(03696)发布公告，英硅智能对外授权给美纳里尼集团(美纳里尼)的MEN2501项目已在I期临床试验中完成首例患者给药，根据双方合作协议，英硅智能获得由美纳里尼支付的约3900万港元的最新里程碑付款。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英硅智能(03696)获美纳里尼3900万港元里程碑付款，合作项目MEN2501完成首例患者给药","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["03696","BK1141"],"gpt_icon":0},{"id":"2608894113","title":"英硅智能02月02日遭主力抛售907.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608894113","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608894113?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:15","pubTimestamp":1770020147,"startTime":"0","endTime":"0","summary":"02月02日, 英硅智能股价跌4.21%，报收60.25元，成交金额1.1亿元，换手率0.34%，振幅9.86%，量比0.85。英硅智能今日主力资金净流出907.3万元，上一交易日主力净流出1352.6万元。该股近5个交易日上涨7.59%，主力资金累计净流入434.8万元；近20日主力资金累计净流出1788.9万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202162100a6c974c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202162100a6c974c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","BK1141"],"gpt_icon":0},{"id":"2608894115","title":"下一个“药王”，不在减肥在抗炎？巨头们已砸下百亿赌注！","url":"https://stock-news.laohu8.com/highlight/detail?id=2608894115","media":"求实药社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608894115?lang=zh_cn&edition=full","pubTime":"2026-02-02 12:01","pubTimestamp":1770004877,"startTime":"0","endTime":"0","summary":"NLRP3作为炎症小体的核心传感器，是炎症小体复合物的关键组成部分。这些数据进一步验证着NLRP3抑制剂在控制慢性、低度炎症方面的临床价值。据统计，全球已有百余家药企正在推进超过百款NLRP3抑制剂项目。因此，抑制NLRP3相当于在炎症级联反应的源头“关闸泄洪”，有望同时阻断多条下游炎症通路，且可能避免对整体免疫防御造成全面抑制。NLRP3作为先天免疫的核心组件，其抑制是否会导致机体抗感染能力下降，是需要长期监测的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202131648953f603b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202131648953f603b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","03696"],"gpt_icon":0},{"id":"1138825501","title":"英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1138825501","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138825501?lang=zh_cn&edition=full","pubTime":"2026-01-29 10:28","pubTimestamp":1769653715,"startTime":"0","endTime":"0","summary":"1月29日，$英矽智能$涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。$浙商证券$发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b3d8dd8aabdb42a4c1c2dbc8bb3918bb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["5RE.SI","BK6092","BK6511","01477","03696","BK1141"],"gpt_icon":1},{"id":"2607773319","title":"1+1>2？英硅智能(03696)GIPR拮抗剂联用策略 引爆下一个减重风口","url":"https://stock-news.laohu8.com/highlight/detail?id=2607773319","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607773319?lang=zh_cn&edition=full","pubTime":"2026-01-29 10:05","pubTimestamp":1769652353,"startTime":"0","endTime":"0","summary":"近日，英硅智能宣布发现创新GIPR拮抗剂ISM0676，该候选分子在临床前小鼠模型中实现用药27天减重31%的强大疗效，为评估GIPR通路在减重治疗中的作用提供了新的临床前数据。一些研发方向将目光投向GIPR拮抗剂与GLP-1R激动剂的联用策略，希望在实现减重的同时有效保留肌肉量。此外，ISM0676单药组在该模型下也显示约10.4%的体重下降。上述结果为“GIPR拮抗剂与GLP-1联用”策略提供了进一步的临床前依据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","GIPR","03696","BK4160"],"gpt_icon":1},{"id":"2607771724","title":"AI制药迎来关键突破期，成为资本押注的重点","url":"https://stock-news.laohu8.com/highlight/detail?id=2607771724","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607771724?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:43","pubTimestamp":1769593382,"startTime":"0","endTime":"0","summary":"AI制药核心价值在于大幅提升药物早研效率，从AI制药市场空间来看，全球AI赋能药物研发费用市场规模将由2023年的119亿美元增长至2032年的746亿美元，CAGR约23%。回顾2025年AI制药迎来关键突破期，不仅融资热度不减，更实现了上市层面的重大进展。如，英硅智能在2025年完成大额融资并成功上市，成为AI制药领域商业化落地的重要里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128185925a45ff534&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128185925a45ff534&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","01477","BK1191","BK1574","BK1141"],"gpt_icon":0},{"id":"2606357497","title":"英硅智能01月27日主力净流入1143.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2606357497","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606357497?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:15","pubTimestamp":1769501751,"startTime":"0","endTime":"0","summary":"01月27日, 英硅智能股价涨7.15%，报收60.70元，成交金额1.6亿元，换手率0.47%，振幅12.80%，量比1.10。英硅智能今日主力资金净流入1143.1万元，上一交易日主力净流出1200.9万元。该股近5个交易日上涨14.80%，主力资金累计净流入1580.2万元；近20日主力资金累计净流出877.0万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127162242a6b222e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127162242a6b222e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","03696"],"gpt_icon":0},{"id":"2606206727","title":"2025年中国创新药对外授权交易额超1300亿美元创纪录","url":"https://stock-news.laohu8.com/highlight/detail?id=2606206727","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606206727?lang=zh_cn&edition=full","pubTime":"2026-01-27 15:31","pubTimestamp":1769499062,"startTime":"0","endTime":"0","summary":"2025年，中国创新药对外授权交易总金额超过1300亿美元，交易数量逾150笔，占全球总量约40%，创下历史新高。阿斯利康在2025年3月初宣布25亿美元投资计划，涵盖三项BD交易及一笔收购。辉瑞与三生制药于2025年5月达成的交易刷新中国创新药出海首付款纪录，达12.5亿美元；礼来全部4笔交易均为技术平台合作，其中2笔涉及晶泰控股与英硅智能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127153959a6b1f6d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127153959a6b1f6d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01530","BK1161","01801","02509","03696","02142","06978","01093","01276","03692"],"gpt_icon":0},{"id":"2606735746","title":"1个月不到，英硅智能已达成3笔重要合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2606735746","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606735746?lang=zh_cn&edition=full","pubTime":"2026-01-27 14:41","pubTimestamp":1769496060,"startTime":"0","endTime":"0","summary":"近年来，AI成制药行业提升研发效率、分散风险的核心工具，英硅智能凭借独特AI平台和已验证的商业化效率，成为不少药企合作对象。此外，英硅智能近年来研发合作不断加速，2022年与复星医药、2024年与赛诺菲等均有合作，2025年12月中旬还将肾性贫血管线大中华区权益授权给太景生物科技。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127150535a6b1d70d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127150535a6b1d70d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","BK1141"],"gpt_icon":0},{"id":"2606735741","title":"一月三笔 BD 交易！这家 Biotech 正在狂飙","url":"https://stock-news.laohu8.com/highlight/detail?id=2606735741","media":"丁香园 Insight 数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606735741?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:31","pubTimestamp":1769484666,"startTime":"0","endTime":"0","summary":"从施维雅，到衡泰生物，再到齐鲁制药，英硅智能横跨肿瘤、神经、代谢三大黄金赛道，连落三子，BD累计总金额已突破 10 亿美金。根据协议条款，英硅智能将授予衡泰生物对 ISM8969 在全球范围内进行研究、开发、注册、生产和商业化的50% 权利。与此同时，英硅智能有权获得总额最高逾 5 亿港币的预付款及里程碑付款，其中包括一笔预计将在协议生效日起 30 日内支付的7800 万港币预付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012713150397a38a53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012713150397a38a53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","BK1141"],"gpt_icon":0},{"id":"2606735710","title":"AI制药BD又一例！","url":"https://stock-news.laohu8.com/highlight/detail?id=2606735710","media":"科创日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606735710?lang=zh_cn&edition=full","pubTime":"2026-01-27 10:58","pubTimestamp":1769482697,"startTime":"0","endTime":"0","summary":"不过，目前为止该公司在AI制药领域动作最为频繁：1月5日，其宣布与施维雅达成一项价值8.88亿美元的抗肿瘤药物研发协议。因此快速投入与布局AI制药与医疗将是业内企业必配。浙商证券强调，AI制药核心价值在于大幅提升药物早研效率，以英硅智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012713343997a38b6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012713343997a38b6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1574","03696","01477","BK1191"],"gpt_icon":0},{"id":"1132298568","title":"港股异动 | 英矽智能涨超5%，与齐鲁制药达成逾9.31亿港元药物研发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1132298568","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132298568?lang=zh_cn&edition=full","pubTime":"2026-01-27 10:25","pubTimestamp":1769480736,"startTime":"0","endTime":"0","summary":"1月27日，英矽智能盘中涨超5%，公司与齐鲁制药达成逾9.31亿港元药物研发合作。消息面上，1月27日，英矽智能发布公告，英矽智能已与齐鲁制药集团及其附属公司上海齐鲁制药研究中心，达成药物研发战略合作并签署相关协议。透过该合作，双方将依托英矽智能自有Pharma.AI解决方案，针对特定靶点开展小分子抑制剂合作开发，关注心血管与代谢类疾病领域管理。根据该协议的条款，英矽智能将利用自主搭建的Pharma.AI平台，关注用于代谢疾病领域的新颖小分子药物设计与优化，齐鲁制药将负责后续开发与商业化工作。该协议总额超9.31亿港元，包含开发和销售里程碑付款，以及单位数的后续净销售额分成。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d697236d2e102256f5a8be78146b39b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1397736.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"港股异动 | 英矽智能涨超5%，与齐鲁制药达成逾9.31亿港元药物研发合作","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["03696","BK1191","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://insilico.com","stockEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.7829},{"period":"3month","weight":1.8274},{"period":"ytd","weight":0.8309}],"compareEarnings":[{"period":"1week","weight":-0.0387},{"period":"1month","weight":0.0065},{"period":"3month","weight":0.0245},{"period":"6month","weight":0.0815},{"period":"1year","weight":0.3053},{"period":"ytd","weight":0.049}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"英矽智能是一家主要从事人工智能在制药领域研发的公司。该公司致力于药物发现引擎的研发，并从事联合用药的发现和开发，包括疾病靶点识别、新分子数据生成以及临床试验结果预测。","exchange":"SEHK","name":"英矽智能","nameEN":"INSILICO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英矽智能(03696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英矽智能,03696,英矽智能股票,英矽智能股票老虎,英矽智能股票老虎国际,英矽智能行情,英矽智能股票行情,英矽智能股价,英矽智能股市,英矽智能股票价格,英矽智能股票交易,英矽智能股票购买,英矽智能股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英矽智能(03696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}